

## Index

- 45 and Up Study, 119
- absolute risk  
   absolute risk increase (ARI), 150, 466  
   absolute risk reduction (ARR), 150–1, 155, 466
- accuracy, 76, 80, 82–3, 86, 94, 125, 129, 201–2, 300, 386–7, 391, 393–5 *see also* error, systematic
- active surveillance, 320, 327
- aetiologic fraction *see* attributable fraction; population attributable fraction
- age-specific rates, 51, 57, 451, 455, 457
- AIDS *see* HIV/AIDS
- American Institute of Cancer Research, 307
- analytic studies, 23, 105, 129, 188, 196, 214, 249
- ascertainment bias, 192
- association  
   versus causation, 275–6  
   measures of, 163
- asthma and BMI (body mass index), 255–6
- attack rate, 4, 32, 42, 265 *see also* incidence proportion  
   secondary, 339
- attributable burden, 371
- attributable fraction (AF)  
   calculation of, 149  
   in case-control studies, 139  
   in disease prevention, 154  
   interpretation of, 150–1  
   in population *see* population attributable fraction (PAF)  
   worked example, 150, 164
- attributable proportion *see* attributable fraction
- attributable risk (AR), 147–9, 152, 154, 160  
   *see also* rate difference; risk difference  
   calculation of  
   in case-control studies, 160–1  
   in clinical epidemiology, 150–1  
   in population *see* population attributable risk (PAR)  
   interpretation of, 153–4  
   versus relative risk, 155–6  
   worked example, 155
- attributable risk per cent *see* attributable fraction
- avoidable burden, 372
- Avon Longitudinal Study of Parents and Children (ALSPAC) (UK), 117
- background risk or rate, 147
- BCG vaccination *see* tuberculosis
- beta-carotene, trials for anti-cancer effects, 419
- bias  
   ascertainment or detection, 192  
   healthy worker effect, 193  
   interviewer or observer, 125, 209–10  
   lead-time, 402–6  
   length-time, 402, 407  
   loss to follow-up, 192  
   measurement *see* measurement error, misclassification  
   publication, 291  
   recall, 116, 125, 208–9  
   selection *see* selection bias  
   volunteer, 402
- bicycle helmets and head injury, 161–2, 284
- biological plausibility, as factor in  
   evaluating causality, 283
- birth defects and thalidomide, 122, 307
- ‘blinding’ in clinical trials, 110
- BMI (body mass index) and asthma, 255–6
- brain cancer and mobile phones, 301
- breast cancer  
   control of, 259, 393  
   screening for, 309, 377, 388, 403–6
- British Doctors’ Study, 16, 23–4, 117, 155, 281–2
- burden of disease, 32, 145, 153, 309, 337, 370

- cancer *see also specific types of cancer*
  - and diet, 99
  - beta-carotene trials, 376, 419
  - dedicated websites, 87
  - epidemiology, 5
  - registries, 87, 198, 323
- cardiovascular disease (CVD)
  - and high blood pressure, 364–5
  - definitions, 52
  - mortality rates, 20
  - proposed ‘Polypill’ prevention strategy, 376
  - risk factor profiles in Finland and China, 362
- case-fatality ratio (CFR), 58–9, 71
- case reports, 76–8
- case series, 76–8
- case-cohort studies, 120–1
- case-control studies
  - advantages and disadvantages of, 121, 123
  - attributable risk in, 160–1
  - confounding in, 242, 418
  - control selection for, 194
  - design of, 122–3
  - hospital controls, 252
  - matching in, 232–3
  - measuring relative risk in, 157–8
  - misclassification in, 205, 208
  - nested case-control study, 120–1, 433
  - odds ratios for, 160
  - population attributable fraction in, 160
  - recall bias in, 125, 209, 212
  - selection bias in, 125, 196, 198
- case-crossover study, 126
- case-finding, versus screening, 385
- case-reference (or case-referent) studies
  - see* case-control studies
- causation
  - causal reasoning, 279–80
  - component cause, 272
  - definitions of causes, 272
  - evaluation of, 283–5
  - models of, 338
  - necessary cause, 271
  - sufficient cause, 271
  - versus association, 275–6
- Centers for Disease Control and Prevention (CDC) (USA), 346, 414
- CER *see* control event rate
- cervical cancer
  - and human papillomavirus (HPV) infection, 382, 425
  - screening programmes for, 383
- CFR *see* case-fatality ratio
- chance (random sampling error), 170–1
  - assessment of effects of, 214
  - confidence intervals, 173–4
  - hypothesis testing, 171, 173
  - multiple testing, 180
  - power, 175–6
  - p-values, 174–5, 177
  - type I error, 172
  - type II error, 171, 175
- CHD *see* coronary heart disease
- child death rate, 61
- childhood mortality and vitamin A, 109, 109
- cholera epidemic, John Snow investigation of, 16, 275
- cholesterol and ischaemic heart disease, 366
- CI *see* confidence intervals
- cigarette smoking *see* smoking
- clinical epidemiology, 6
  - attributable risk in, 150–1
  - incidence proportion in, 46, 47
  - diagnostic studies, 129
  - number needed to treat (NNT), 151
  - predictive values in, 394–5
  - prognostic studies, 120
  - relative risk in, 145–6
- clinical significance, 181, 260
- clinical trials *see* randomised controlled trials
- clusters, 335–6
  - definitions of, 343
  - examples of, 335
  - investigation of, 343–4
- Cochrane Collaboration database, 258–9
- cohort studies, 99, 105, 116–20
  - 45 and Up Study, 118
  - advantages and disadvantages of, 116
  - Avon Longitudinal Study of Parents and Children (ALSPAC) (UK), 117
  - British Doctors Study, 117

- case-cohort studies, 120–1
- confounding in, 200, 210, 225
- design of, 114
- European Prospective Investigation into Cancer (EPIC), 433
- Framingham Heart Study, 115
- generalisability, 116
- internal validity, 188
- loss to follow-up, 189, 192
- Million Women Study, 433
- misclassification in, 116
- nested case-control studies, 121
- Nurses' Health Study, 116–17, 188
- prognostic studies, 120
- record linkage, 118–19
- retrospective or historical, 118
- selection bias in, 188–9
- communicable diseases *see* infectious diseases
- community trials, 113 *see also* intervention studies
- component cause, 271–4, 286
- conditional logistic regression, 238
- confidence intervals (CI), 173–4
  - and *p*-values, 174–5, 177–8
  - evaluating role of chance, 181
- confidentiality, 100
- confounding, 28, 217–45
  - and study size, 235
  - assessment of effects, 243
  - by indication, 230–1
  - common confounders, 223
  - conditions for confounding to occur, 225–8
  - control through data analysis, 235–43
  - control through study design, 230–5
  - criteria for a confounder, 221–3
  - versus effect modification, 236–7
  - effects of, 223–8
  - example of, 219–21
  - in a case-control study, 219, 227, 233
  - cohort study, 218, 225
  - in an ecological study, 99
  - matching, to control, 232–3
  - modelling, to control, 238
  - randomisation, to control, 230–1
  - residual, 240–3
  - restriction, to control, 231–2
  - Simpson's paradox, 217, 223
  - stratification, to control, 235–8
- congenital abnormalities and rubella, 38
- consistency, as factor in evaluating causality, 281, 302
- control event rate (CER), 47, 146 *see also* incidence proportion
- control group *see also* case-control studies
  - hospital controls, 124–5
  - population controls, 124
- coronary heart disease (CHD) *see also*
  - cardiovascular disease, ischaemic heart disease
  - and smoking, 182, 281
  - terminology, 52
  - registries (MONICA Programme), 88
- correlation studies *see* ecological studies
- Counterfactual, 107, 111, 272, 279–80
- Cox proportional hazards regression, 238
- Creutzfeldt-Jacob disease (CJD)
  - and blood transfusions, 252–3
- critical point, in the disease process, 385
- cross-level bias, 48, *see also* ecological fallacy
- cross-sectional studies, 127–9
  - avoiding selection bias, 128
  - design of, 127
  - recall bias, 209
- crossover trial, 111–12
- crude rates, 49, 51
- cumulative incidence (CI) *see* incidence proportion
- CVD *see* cardiovascular disease
- DALY *see* disability-adjusted life year
- data analysis
  - conditional logistic regression, 238
  - Cox proportional hazards modelling, 238
  - matched data, 233–4
  - multiple logistic regression, 238
  - multivariable modelling, 238
- death
  - certificates, 80, 83, 86
  - establishing cause of, 49, 66, 80, 83
  - national registers, 81
  - rates *see* mortality rates
- Declaration of Helsinki, 131
- Demographic and Health Surveys (DHS), 93

- density sampling, 159
- depression, risk factors for, 257
- descriptive epidemiology, 7, 13, 23, 41, 333
- descriptive studies, 196
  - assessing results of, 263–4
  - by person, place and time, 19–20, 22
  - selection bias in, 188
- detection bias, 192
- diabetes (mellitus)
  - and BMI (body mass index), 282, 370
  - gestational, 33–4
  - mortality and ICD changes (USA), 85
- diagnostic criteria, 33
- diagnostic studies, 129, 390
- diagnostic tests
  - accuracy and predictive values, 395
- diet and cancer, 24
- diethylstilboestrol (DES) exposure and vaginal cancer risk, 176
- difference measures *see* attributable risk;  
rate difference; risk difference
- differential error/misclassification
  - estimation of effects of, 197
  - sources, 197
- directed acyclic graphs, 223, 229–30
- direct standardisation, 52, 57, 147, 451
- disability-free life expectancy, 64–5
- disability-adjusted life years (DALY), 31, 68–70
- disease
  - diagnostic criteria, 33
  - endemic and epidemic, 470
  - natural history of, 18
  - prognosis, 18
  - transmission, 13
- Doll, Sir Richard, 16–17, 23–4
- dose-response relationships, in evaluating causality, 269, 282
- ecological fallacy, 48, 99, 470
- ecological studies, 62, 98–9, 103–4, 129–30, 134, 250, 409–10, 432, 468, 470
- EER *see* experimental event rate
- effect modification, 236–7, 470, 481
- eligibility and exclusion criteria, 195
- endemic disease, 336–8
- epidemic (outbreak)
  - common conditions for occurrence/cessation, 41
  - curve, 15, 348–9
  - definition of, 8–11
  - examples of, 19
  - index case, 129
  - investigation of, 4
  - management of, 345–6
  - point-source, 348
  - prevention, 357
  - propagative (contagious), 349
  - tuberculosis, a case study, 347
- epidemiology
  - analytic, 105, 419
  - boundaries of, 5
  - cancer, 5
  - clinical, 6, 46, 150–1
  - definitions of, 2
  - descriptive, 7, 13, 23, 41, 75, 105, 333, 426
  - environmental, 5
  - historical beginnings, 8–10
  - infectious diseases, 4, 336–8
  - injury, 5
  - lifecourse, 6, 106, 423
  - molecular, 6, 299
  - nutritional, 4, 24
  - occupational, 5
  - perinatal, 5
  - pharmacoepidemiology, 126
  - public health, 6, 23
  - scope of, 2
  - social, 4, 106
- error, sources of *see also* selection bias,  
measurement error, misclassification
  - in subject selection *see* selection bias
  - in measurement *see* measurement error
  - random, 183, 201
  - systematic, 201–2
- ethics, 130–1
  - Declaration of Helsinki, 131
  - Nuremberg Code, 131–3
- European Prospective Investigation into Cancer (EPIC), 116
- excess rate/risk *see* rate/risk difference
- exchangeability, 107, 109, 111, 112, 140, 188, 235, 241, 425
- exclusion criteria, 195
- expected years of life lost (EYLL), 65–6
- experimental event rate (EER), 47, 146
  - see also* incidence proportion

- experimental studies *see* intervention studies
- external validity of results, 188
- Farr, William (1807–1883), 13, 275
- follow-up studies *see* cohort studies
- force of morbidity, 44, 471
- forest plots, 294, 297
- Framingham Heart Study, 115–16, 188
- gastric cancer *see* stomach cancer
- generalisability (external validity), 116, 128, 188, 248, 262–3
- genetic versus environmental effects, 18
- gestational diabetes, 33–4
- global warming, and infection risks, 337
- Goldberger, Joseph (1620–1674) and pellagra, 16
- Graunt, John (1620–1674, 11–13
- HALE *see* health-adjusted life expectancy
- hazard ratio, 233, 238
- head injury and bicycle helmets, 161–3, 284
- health, definition of, 18
- health data
- ethical use of, 100
  - morbidity data, 77, 87
  - mortality data, 19, 49, 79, 86, 275, 377
  - privacy concerns, 119
  - sources of summary, 77
- Health Insurance Plan (HIP), study of breast cancer screening, 404
- health-adjusted life expectancy (HALE), 2, 31, 67, 471
- health-adjusted life years
- disability-adjusted life years (DALY), 31, 68, 70
  - quality-adjusted life years (QALY), 31, 66
- Health and Demographic Surveillance Systems (HDSS), 82–3
- health expectancy, measures of, 65, 471
- health gaps, measures of, 65, 69, 471
- healthy-worker effect, 192–3, 472
- heart attack *see* myocardial infarction
- heart disease *see* coronary heart disease; ischaemic heart disease; cardiovascular disease
- Helicobacter pylori* infection and stomach cancer, 97, 250, 285
- hepatitis
- A and C, 393
  - surveillance for hepatitis C, 39
- heterogeneity, of study results, 237, 281, 294, 298, 300, 302, 304, 472
- high blood pressure, and CVD, 364
- high-risk strategy for disease prevention, 367, 370
- Hill, Sir Austin Bradford, 278
- Hippocrates of Cos, 11
- historical cohort study, 118–19, 232, 479
- HIV/AIDS
- identification of, 34
  - prevalence and incidence rates, 34–6
  - screening of blood donors, example, 391–4
- hospital records, for morbidity data, 86, 88
- host *see* infectious diseases, host factors
- human papillomavirus (HPV) infection, and cervical cancer, 232, 425–6
- Human Research Ethics Committee (HREC), 100, 130
- Hume, David (Hume's problem), 277
- hypothesis testing
- and *p*-values, 174–5
  - type I error, 171
  - confirmation and refutation, 277
  - power and type II error, 175–6
- IHD *see* ischaemic heart disease
- incidence *see also* incidence proportion; incidence rate
- relationship with prevalence and duration, 39–40
  - standardised incidence ratio (SIR), 52, 56–7
- incidence density *see* incidence rate
- incidence proportion, 41–2 *see also* attack rate
- calculation of, 43
  - control event rate (CER), 47
  - definition, 43
  - experimental event rate (EER), 47
  - from routine data, 54–5
  - measurement in epidemiological studies, 46
  - versus incidence rate, 44–5
- incidence rate (IR), 46–8
- age-specific, 50–1

- incidence rate (IR) (cont.)
  - calculation of, 43–4
  - definition of, 43
  - crude, 49–50
  - from routine data, 48–9
  - measurement in epidemiological studies, 41–3, 46–8
  - incidence rate difference, 42
  - incidence rate ratio, 158, 233, 238
  - standardised, 52–3
  - stroke and smoking, 140, 147
  - versus incidence proportion, 44–5
- incubation period for disease, 317, 334, 340, 348, 351, 473
- Indigenous Australians, mortality ratios, 19, 56
- indirect standardisation, 57–8, 457, 473
- infant mortality rate, 11, 61–3, 67
- infection *see also* infectious agents;  
infectious diseases
  - control of, 340
  - definition of, 7
  - elimination of, 316
  - eradication of, 316
  - intensity of, 473
- infectious agents
  - case-fatality ratio (CFR), 339
  - incubation period, 340
  - infectivity, 339
  - infestation, 339
  - intensity of infection, 339
  - latent period, 340
  - pathogenicity, 339
  - reservoirs, 339
  - secondary attack rate, 339
  - sources, 340
  - transmission of, 340–2
  - virulence, 339
- infectious diseases
  - and environmental change, 342
  - causal models, 338–9
  - definition, 336
  - endemic, epidemic, pandemic, 335–6
  - epidemiology of, 335–8
  - factors affecting spread, 335
  - host factors, 340
- infectivity, 339, 473, 479
- infestation, 339, 473
- influenza
  - H1N1 ('swine flu') outbreaks, 77, 325, 336, 384
  - H5N1 (avian influenza) outbreaks, 325, 337
- information error *see* measurement error
- injury epidemiology, 5
- Institutional Review Board *see* Human Research Ethics Committee
- intention to treat analysis, 231, 403, 473
- internal validity of results, vii, 188–9, 252, 260
- International Agency for Research on Cancer (IARC), 87, 94, 288, 306
- interval cases, 473
- intervention studies, 24, 108–9 *see also* randomised controlled trials
  - community trials, 113
  - field trial of polio vaccine, 108
- International Studies of Infarct Survival (ISIS), 108
- vitamin A and childhood mortality, 109
- water fluoridation and dental health, 113
- interviewer bias, 254
- ischaemic heart disease *see also* cardiovascular disease, coronary heart disease
  - DALYs due to, 274
  - terminology, 365
  - inverse association with wine consumption, 99
  - mortality rates, 50–3
  - serum cholesterol level and, 365
- instrumental variables, 241–2, 424
- International Studies of Infarct Survival (ISIS), 108
- kidney disease, and phenacetin, 123
- Kinsey, studies of sexual behaviour, 190
- latent period of infection, 340
- lead-time, 402
- lead-time bias, in screening programmes, 403, 406
- length-time bias, in screening programmes, 407
- life expectancy, 63–4
  - disability-free life expectancy, 64–5
  - health-adjusted life expectancy (HALE), 67

- lifecourse epidemiology, 6, 106, 423
- life-table, 11, 64
- lifetime risk, from routine data, 55
- Lind, James and scurvy, 108
- logistic regression, 238
- loss to follow-up, 192
  - sensitivity analysis for, 199–200
- lung cancer
  - and smoking, 16, 55, 70, 95, 106, 141–2, 148, 218, 223
  - British Doctors Study, 16, 24, 41, 117, 155
  - control of, 118, 363
  - mortality rates, 7, 94, 155
- mammography
  - debate concerning, 308
  - screening for breast cancer, 404
- Mantel-Haenszel odds ratio, 464–5
- mass strategy for disease prevention, 356, 368
- matching, to control confounding, 232–3, 235
  - analysis of matched data, 234
  - frequency matching, 232–3
  - individual, 234
- maternal mortality rate, 61
- measles
  - infectivity and pathogenicity, 339
  - vaccination strategy, 337
- measurement error, 203, 205 *see also*
  - misclassification
  - assessing effects, 212
  - control of, 210
  - effects, 202
  - overview of, 212
  - random error, 187, 201–2, 204, 212
  - sources of, 208
  - systematic error, 187, 201, 204–5, 212
- measures of association, 57, 140, 159, 188, 351
  - attributable risk, 147–8, 150, 154
  - relative risk, 142, 157
  - worked example, 163
- measures of disease
  - incidence rate, 38, 41, 43, 46, 147, 151
  - incidence rate versus incidence proportion, 44–5
  - prevalence, 34–6, 38, 41, 45, 189, 194, 369, 393
  - summary of, 71
  - use of percentages, 37
  - using routine data, 48
- MEDLINE database, 290–1
- Mendelian randomisation, 242
- meta-analysis, 178, 294, 297, 299, 465
- MI *see* myocardial infarction
- migrant studies, 96
- Millennium Development Goals, 60–1, 80, 87, 93, 427
- Million Women Study (UK), 116
- misclassification, 200, 203 *see also*
  - measurement error
  - differential, 205–7
  - assessment of effect of, 212–13
  - non-differential, 203–4, 206
- molecular epidemiology, 299
- morbidity, force of, 44
- morbidity data, 86–9
- mortality data, 49, 76–7, 79–83, 85–6
  - death certificates, 80, 86
  - establishing cause of death, 49, 66, 80, 83, 193
- mortality rates, 21, 49
  - age-specific, 50
  - all-cause, 22, 55
  - cardiovascular disease (CVD), 20, 52, 404
  - child death rate, 61, 109
  - childbirth and early life, 11, 13, 60
  - crude mortality rates, 49–51, 53
  - Indigenous Australians, 19–20
  - infant mortality rate, 61–2, 67
  - lung cancer, 7, 17, 22, 94, 96, 155
  - maternal mortality rate, 61
  - neonatal mortality rate, 61
  - proportional mortality ratio (PMR), 58, 71
  - Russian men, 7, 68
  - standardised, 20, 49, 52, 54
  - stillbirth or fetal death rate, 61–2
  - stillbirth or fetal death ratio, 61–2
  - trends in USA, 55
- multiple logistic regression *see* logistic regression
- multivariable modelling, 238–40
- myocardial infarction (MI), heart attack and sexual activity, 126
- International Studies of Infarct Survival (ISIS), 108
- mortality and streptokinase, 109
- terminology, 59

- n*-of-1 randomised trials, 112
- National Health and Nutrition Examination Surveys (NHANES), 91–2
- narrative reviews, 289
- natural history of disease, 18, 384, 386
- necessary cause, 271–3, 317, 336, 382
- negative predictive value (NPV), 390
- neonatal mortality rate, 61, 67
- nested case–control studies, 120–1, 433
- NNT *see* number needed to treat
- non-differential error/misclassification, 203–4, 214
  - estimation of effects of, 197
- notifiable diseases, 87 *see also* surveillance
- number needed to treat (NNT), 151
- Nuremberg Code, 131–2
- Nurses' Health Study (USA), 24, 116–17, 282
- nutritional epidemiology, 5, 24
- obesity
  - CVD and, 363
  - epidemic, 63
  - ovarian cancer and, 296–7
- observation versus randomisation, 295
- observational studies, 114–15, 117–22, 124–30, 242, 302–3, 419–20
- observer bias, 209
- occupational epidemiology, 5
  - use of proportional mortality ratio (PMR), 57–8
- odds ratio, 157–9, 179, 198, 204, 206, 213, 219–20, 236, 253
  - adjusted, 464
  - and relative risk, 157–60, 461
  - in a cross-sectional study, 41, 160
  - interpretation of, 158, 160
  - Mantel-Haenszel, 464–5
  - matched, 234
  - pooled, 220, 464–5
- oesophageal cancer and smoking, 253
- oral contraceptive use
  - and CHD, 226
  - and ovarian cancer risk, 122
  - and pulmonary embolism, 78
- outbreak *see* epidemic
- ovarian cancer
  - and obesity, 296–7
  - and oral contraceptive use, 122, 157, 361
  - and smoking, 195, 425
- pandemic, 336
- PAF *see* population attributable fraction
- PAR *see* population attributable risk
- passive health surveillance, 320
- Pasteur, Louis, 342
- pathogenicity, 339
- pellagra, 16
- person-years, 42–3, 141, 245
- pharmacoepidemiology, 124, 126
- phenacetin and kidney disease, 123
- phenylketonuria (PKU), screening of new-borns, 387
- Physicians' Health Study, 108, 376
- PMR *see* proportional (or proportionate) mortality ratio
- Pneumocystis carinii* pneumonia cluster and discovery of HIV/AIDS, 78
- point-source epidemic, 348
- polio (poliomyelitis)
  - surveillance for, 319
  - eradication and surveillance programmes, 319
  - field trial of polio vaccine, 108
  - infectivity, pathogenicity and virulence of virus, 339
- 'Polypill' for CVD prevention, 376
- pooled analysis (re-analysis), 299
- pooled odds ratios, 464–5
- Popper, Karl and causal hypotheses, 277
- population
  - study, 89, 90, 183, 194, 262
  - target, 89, 90, 170, 183, 188, 194, 296, 395
  - sampling, 90
- population at risk, 39, 42, 61
- population attributable fraction (PAF)
  - see also* attributable fraction
  - and world health, 154
  - as a guide to prevention, 370–1
  - calculation of, 153, 160–1, 165
  - in case–control studies, 160
  - interpretation of, 150, 153–5
  - worked example, 165
- population attributable risk *see also* attributable risk
  - calculation of, 152
  - interpretation of, 153, 155
  - worked example, 164
- population attributable risk per cent *see* population attributable fraction



- population strategy for disease prevention, 368
- positive predictive value (PPV), 391, 412
- post-test probability, 395 *see also* predictive values
- potential impact fraction (PIF), 372
- potential years of life lost (PYLL), 65–6, 69
- power of a study, 176
- precision *see* random error
- predictive values (PPV and NPV), 391, 393, 412
- pre-test probability, 395 *see also* prevalence
- prevalence (P), 32, 35–6, 38–41, 45
  - calculation, 32, 35, 41
  - definition, 36
  - measurement in epidemiological studies, 41–2
  - period prevalence, 36
  - point prevalence, 36
  - pre-test probability, 395
  - relationship with incidence and duration, 39–40
  - ratios, 143, 145, 160
  - in cross-sectional studies, 127
- prevalence surveys, 89
  - selection bias in, 188
- prevention paradox, 378
- prevention
  - evaluation of prevention programmes, 18, 373
  - high-risk strategy, 366–7
  - mass or population strategy, 368
  - ‘middle-road’ strategy, 369
  - paradox, 378
  - population attributable fraction (PAF) as a guide, 370–1
  - primary, 356–8
  - primordial, 358
  - secondary, 356, 378
  - suicide prevention programme (US Air Force), 374, 376
  - tertiary, 356
- prognosis of disease, 18
- prognostic studies, 120
- propagative epidemics, 349
- propensity scores, 231, 241
- proportional (or proportionate) mortality ratio, 57–8
- proportions, ratios and rates, 56
- prospective studies *see* cohort studies
- prostate cancer
  - screening for, 305, 386
- publication bias, 291
- pulmonary embolism and oral
  - contraceptive use, 78
- p*-values and statistical significance, 179, 182
  - and confidence intervals, 174, 177
- PYLL *see* potential years of life lost
- quality-adjusted life years (QALY), 31, 66–7
- random error, 201–2, 205, 207
  - assessing effects on reported results, 203
  - in measurement, 201
  - in subject selection (sampling), 214 *see also* chance
- randomisation
  - to control confounding, 241
  - versus observation, 295
- randomised controlled trials, 109, 111–14, 181, 235, 278, 290, 303, 433
  - blinding in, 110
  - confounding in, 230–1
  - crossover, 111–12
  - design of, 114
  - estimation of bias from loss to follow-up, 111
  - generalisability of, 263
  - loss to follow-up, 111, 192
  - n*-of-1 trials, 112
  - parallel group, 111
  - selection bias in, 424
- rare disease assumption, 160
- rate difference, 141, 147–8, 156 *see also* attributable risk
- rate ratio (RR), 141–2, 145, 235 *see also* relative risk
- rates, ratios and proportions, 56
- RCTs *see* randomised controlled trials
- reading reports, 248–66
  - assessing results of descriptive studies, 263–4
  - assessing effects of chance, 259
  - assessing the study design, 250–1
  - checking for confounding, 257–8
  - checking for measurement bias, 253–4

- reading reports (cont.)
  - checking for selection bias, 251
  - external validity (generalisability) of results, 262–3
  - identifying the research question, 250
  - internal validity of results, 260
  - writing reports, 264
- recall bias, 116, 205, 208–9, 256
- record linkage, 118–19
  - for surveillance, 263
- relative risk (RR), 4, 20, 28, 142–3, 145, 157, 179 *see also* odds ratio; rate ratio; risk ratio
  - in case-control studies, 156–7
  - in clinical epidemiology, 145–6
  - relative risk increase (RRI), 143, 146
  - relative risk reduction (RRR), 146
  - worked example, 164–5
  - versus attributable risk, 155–6
- relative survival rate, 59
- research designs *see* study designs
- reservoirs of infection, 339–40
- response rates, and selection bias, 190
- restriction, to control confounding, 231
- retrospective cohort study *see* cohort study
- reverse causality, 24, 107, 116, 128
- reviews of literature
  - narrative, 289
  - systematic, 289 *see also* systematic reviews
- risk difference, 149 *see also* attributable risk
- risk ratio (RR), 143–5 *see also* relative risk
- routine data
  - finding, 77–81
  - use in descriptive studies, 93–7
  - use to measure disease occurrence, 48–55
- RR, RRI, RRR *see* relative risk
- rubella and congenital abnormalities, 38
- sampling error (random), 170–1 *see also* chance and sample size (power)
- screening, 381–414 *see also* screening programme, screening test
  - aims of, 383
  - critical point, 385
  - definition of, 382
  - for bowel cancer, 388, 408
  - for breast cancer, 309, 388, 403, 406, 408
    - for cervical cancer, 383, 388, 407, 425
    - for phenylketonuria, 387
    - for prostate cancer, 305, 386, 411
    - relationship to the disease process, 384–5
    - versus case-finding, 385
  - screening programme
    - evaluation of, 401–3
    - lead-time bias, 403, 406
    - length-time bias, 407
    - negative consequences of, 410–11
    - requirements of the programme, 385–91, 393–4
    - requirements of the test, 385
    - sources of bias in evaluation of, 402
    - study designs to evaluate, 407–11
    - suitability of the disease, 386
    - volunteer bias, 402–3
  - screening test, 387
    - false positive and negative result, 389
    - negative predictive value (NPV), 390–1
    - positive predictive value (PPV), 390–1
    - requirements of, 386
    - sensitivity of, 388–90
    - specificity of, 388–90
    - trade-off between sensitivity and specificity, 396–8
    - true positive and negative result, 389
- secondary attack rate, 339
- secondary prevention, 356, 378
- selection bias (systematic sampling error), 90, 124, 128, 170, 187–9, 196, 198, 251–2
  - assessing effects of, 196, 198, 212–13
  - control of, 194
  - effects of low response rates, 190
  - healthy worker effect, 192–3
  - in case-control studies, 195
  - in cohort studies, 189
  - in clinical trials, 214
  - in descriptive studies, 188
  - in evaluation of screening programmes, 401
  - loss to follow-up, 192
  - overview, 187
  - sources of, 189–90
  - sensitivity analysis for, 199–200
  - sensitivity of screening tests, 388, 390, 389
- sensitivity analysis to estimate effects of bias, 199

- sentinel surveillance, 327–9
- severe acute respiratory syndrome (SARS)
  - epidemic (2003)
  - case-fatality rate, 58–9
  - global response to, 59–60
  - identification of, 76, 78
  - management of media, 347
- sexual activity and myocardial infarction (MI, heart attack), 126
- significance
  - statistical, 169, 171
  - statistical versus clinical (or practical), 181–2
- Simpson's paradox, 217, 223
- SIR *see* standardised incidence ratio
- smallpox, 23
  - eradication (1980), 316
- smoking
  - and CHD, 155–6
  - and lung cancer, 16, 23, 95, 142, 218–19, 266
  - and oesophageal cancer, 253
  - and ovarian cancer, 195
  - and Parkinson's disease, 118
  - and response rates, 190
  - and stroke, 97, 115, 140–2, 148, 150–1
  - British Doctors' Study, 16, 23–4, 41, 117, 155, 281–2
- SMR *see* standardised mortality ratio
- Snow, John (1813–1858) and cholera, 13, 14, 14, 15, 275
- social epidemiology, 106
- specificity
  - as factor in evaluating causality, 276
  - of screening tests, 387, 394
- standard populations, 54, 451–3
- standardisation
  - direct, 57, 451
  - indirect, 56–7, 457
  - standardised rates, 49, 53
- standardised incidence ratio (SIR), 52–3, 56–7, 147
- standardised mortality ratio (SMR), 52–3, 56–7, 96, 458
- statistical significance, 169, 171, 177, 182, 260
- stillbirth or fetal death rate, 61, 62
- stillbirth or fetal death ratio, 61, 62
- stomach cancer and *Helicobacter pylori* infection, 97, 250, 285–6
- stratification
  - to control confounding, 241–2
  - to identify confounding, 241–2
- strength of association, in evaluating causation, 176, 280
- streptokinase and heart attack mortality, 109
- stroke and smoking, 97, 115, 140–2, 148, 150–1
- study designs
  - case-cohort, 120
  - case-control, 121–5
  - case-crossover, 125–6
  - cohort, 114–18
  - cross-sectional, 127–8
  - ecological (correlation), 129–30
  - intervention (experimental), 24, 108–9
  - migrant, 96
  - nested case-control, 121
  - pre-post intervention, 113
- study size
  - and confounding, 231, 257
  - and *p*-values, 179
  - and power, 175–6
- subject selection error *see* selection bias
- sudden infant death syndrome (SIDS),
  - study of
    - risk factors, 123
- sufficient cause, 271
- suicide
  - prevention programme (US Air Force), 374
  - rates, 70, 374–5
  - years of potential life lost, 70
- surveillance, 82, 87, 100, 265, 315–16, 318
  - active, 320, 327
  - definition, 318–19
  - digital, 325–7
  - evaluation of surveillance systems, 321
  - event-based, 324–5
  - for drug safety, 119
  - for polio, 319
  - for risk factors, 328
  - indicator-based, 322–4
  - mass-gathering, 327
  - notifiable diseases, 323, 325, 329
  - passive surveillance, 320
  - scope of, 314–15
  - sentinel surveillance, 327–8
  - syndromic, 319–20
  - rumour surveillance, 325

- survival rate and relative survival rate, 59
- systematic reviews, 289
  - assessing heterogeneity, 297
  - assessing the quality of, 303–4
  - assessment of causality, 306
  - graphical display of results, 294
  - identifying the literature, 291
  - inclusion criteria, 292
  - meta-analysis, 297, 299
  - pooled analysis, 299
  - for public health policy, 316
  - publication bias, 291
  - study designs and quality of evidence, 302
  - summarising the data, 294
- TB *see* tuberculosis
- temporality, as factor in evaluating causality, 276
- tertiary prevention, 356
- Thai Health Risk Transition Study, 423
- thalidomide and birth defects, 307
- Titanic sinking, death rates, 10
- transmission of infectious disease
  - airborne, 342
  - and control strategies, 356
  - direct, 341
  - horizontal, 341
  - indirect, 341
  - vectors, 341
  - vehicle, 341
  - vertical, 341
- tuberculosis
  - BCG vaccination, 357–8
  - factors in mortality reduction, 358–9
  - US Physicians’ Health Study, 108
  - USA, trends in mortality rates, 55
  - US Preventive Services Task Force (USPSTF), 288, 294, 303, 305, 309
- vaccination
  - BCG (tuberculosis) vaccination, 357–8
  - benefits and concerns, 265
  - measles, mumps and rubella (MMR) vaccination strategy, 337
- vaginal cancer risk, and diethylstilboestrol (DES) exposure, 176
- validation studies, 211, 213, 256
- validity
  - external (generalisability), 188, 262–3
  - internal, 188–9, 214
- verbal autopsy, 82
- veteran health and mortality rates, 193
- virulence, 339
- vital statistics, 77–81
- vitamin A and childhood mortality, 109
- volunteer bias, 189–90, 402–3
- water fluoridation and dental health, 113
- World Cancer Research Fund (WCRF), 288, 307
- World Health Organization (WHO), 2, 54, 68, 94, 314, 371
  - Global Health Observatory, 94
- World Health Report, 70
- writing papers, 264
- years of potential life lost *see* potential years of life lost, expected years of life lost
- zoonoses, 337, 341